Immunohistochemical detection of the chondroitin sulfate proteoglycan 4 protein in primary and metastatic melanoma.
CSPG4
immunohistochemistry
metastatic melanoma
primary melanoma
tumor antigen
Journal
Oncology letters
ISSN: 1792-1082
Titre abrégé: Oncol Lett
Pays: Greece
ID NLM: 101531236
Informations de publication
Date de publication:
Sep 2023
Sep 2023
Historique:
received:
02
03
2023
accepted:
22
06
2023
medline:
10
8
2023
pubmed:
10
8
2023
entrez:
10
8
2023
Statut:
epublish
Résumé
Treatment of malignant melanoma, the most aggressive form of skin cancer, continues to be a major challenge for clinicians. New targeted therapies with kinase inhibitors or drugs which modify the immune response are often accompanied by the development of resistance or severe side effects. In this context, chondroitin sulfate proteoglycan 4 (CSPG4), a highly immunogenic melanoma tumor antigen, could be a potential target for alternative therapeutic approaches. The aim of the present study was to identify differences in the levels of CSPG4 protein expression in primary and metastatic melanomas as well as to analyze correlations between CSPG4 expression and histopathological data and patient characteristics. A total of 189 melanoma tissue samples from Lower Austria, including primary melanomas and melanoma metastases, were immunohistochemically stained for the expression of CSPG4 and statistical analyses were performed. A total of 65.6% of melanoma tissue samples stained positive for the expression of CSPG4. Primary nodular and primary superficial spreading melanomas demonstrated a significantly higher number of positively stained tissue samples for CSPG4 compared with primary lentigo maligna melanomas. No significant differences in the expression of CSPG4 were demonstrated between primary melanomas and melanoma metastases. The present study supports the advancement of the understanding of CSPG4 tissue expression patterns in melanoma patients and provides additional information for further investigation of CSPG4 as a potential therapeutic target.
Identifiants
pubmed: 37559576
doi: 10.3892/ol.2023.13968
pii: OL-26-3-13968
pmc: PMC10407859
doi:
Types de publication
Journal Article
Langues
eng
Pagination
382Informations de copyright
Copyright: © Grossauer et al.
Déclaration de conflit d'intérêts
The authors declare that they have no competing interests.
Références
Immunol Res. 2011 Aug;50(2-3):294-302
pubmed: 21717063
Expert Opin Ther Targets. 2015;19(10):1339-50
pubmed: 26190756
Nat Med. 2019 Jun;25(6):936-940
pubmed: 31171879
Lancet. 2015 Aug 1;386(9992):444-51
pubmed: 26037941
N Engl J Med. 2015 Jan 1;372(1):30-9
pubmed: 25399551
Br J Ophthalmol. 2003 May;87(5):629-32
pubmed: 12714409
Int J Oncol. 2015 Jul;47(1):81-90
pubmed: 25997619
Ther Adv Med Oncol. 2019 Jun 06;11:1758835919855491
pubmed: 31217827
Curr Mol Med. 2010 Jun;10(4):419-29
pubmed: 20455858
J Immunother Cancer. 2014 Aug 19;2:25
pubmed: 25197555
Proc Natl Acad Sci U S A. 1982 Feb;79(4):1245-9
pubmed: 6175965
Cancer Res. 2009 Oct 1;69(19):7538-47
pubmed: 19738072
J Clin Invest. 1990 Dec;86(6):2136-44
pubmed: 2254463
Eur J Dermatol. 2013 Nov-Dec;23(6):872-8
pubmed: 24184485
Cancer Res. 2010 Apr 15;70(8):3027-33
pubmed: 20395199
Cancer Res. 1991 Mar 15;51(6):1726-32
pubmed: 1671829
J Immunol. 2005 Jan 15;174(2):976-82
pubmed: 15634921
J Natl Cancer Inst. 1985 Feb;74(2):299-306
pubmed: 3883034
Eur J Cancer. 2016 Mar;56:45-53
pubmed: 26802530
Pigment Cell Melanoma Res. 2011 Dec;24(6):1148-57
pubmed: 22004131
N Engl J Med. 2010 Aug 19;363(8):711-23
pubmed: 20525992
Cancer Res. 1993 Jun 15;53(12):2830-3
pubmed: 8504426
J Biol Response Mod. 1987 Aug;6(4):457-72
pubmed: 3625231
Oncoimmunology. 2012 Dec 1;1(9):1620-1622
pubmed: 23264914
Lancet. 2017 Oct 21;390(10105):1853-1862
pubmed: 28822576
Lancet Oncol. 2015 May;16(5):522-30
pubmed: 25840693
Mol Oncol. 2008 Apr;1(4):395-405
pubmed: 19383313
Recent Results Cancer Res. 2001;158:249-64
pubmed: 11092052
N Engl J Med. 2017 Nov 9;377(19):1824-1835
pubmed: 28891423
Int J Cancer. 2005 Apr 10;114(3):426-32
pubmed: 15578703
BMC Cancer. 2016 Aug 30;16:691
pubmed: 27576582
Clin Cancer Res. 2008 Dec 15;14(24):8178-83
pubmed: 19088033
Proc Natl Acad Sci U S A. 1996 Sep 3;93(18):9710-5
pubmed: 8790396
Mol Cancer. 2010 Nov 23;9:301
pubmed: 21092273
J Cutan Pathol. 1983 Aug;10(4):225-37
pubmed: 6350388
Front Immunol. 2018 Jan 10;8:1911
pubmed: 29375561
Cancers (Basel). 2020 Apr 22;12(4):
pubmed: 32331483
Cancer Biol Ther. 2005 Dec;4(12):1318-24
pubmed: 16322682
Cancer Res. 2005 Aug 1;65(15):6976-83
pubmed: 16061683
Int J Cancer. 1994 Feb 1;56(3):370-4
pubmed: 8314324
Clin Cancer Res. 2014 Feb 15;20(4):962-71
pubmed: 24334762
Transl Oncol. 2022 Feb;16:101318
pubmed: 34942534
Biosci Trends. 2010 Apr;4(2):86-9
pubmed: 20448346
J Cell Biol. 2004 Jun 21;165(6):881-91
pubmed: 15210734
J Immunother. 2011 Oct;34(8):597-605
pubmed: 21904216
J Cell Biol. 2007 Jul 2;178(1):155-65
pubmed: 17591920
Cancer Immunol Immunother. 2015 Dec;64(12):1623-35
pubmed: 26515978
Oncol Res. 2015;22(2):117-21
pubmed: 25706398
CA Cancer J Clin. 2017 Nov;67(6):472-492
pubmed: 29028110
N Engl J Med. 2015 Jun 25;372(26):2521-32
pubmed: 25891173
Proc Natl Acad Sci U S A. 1992 Jan 15;89(2):466-70
pubmed: 1731316
J Clin Oncol. 1984 Nov;2(11):1235-44
pubmed: 6333489
PLoS One. 2014 Jun 16;9(6):e100178
pubmed: 24932730
Int J Oncol. 2021 Sep;59(3):
pubmed: 34318902
Eur J Cancer. 2015 Oct;51(15):2179-2190
pubmed: 26421821
Immunotherapy. 2011 Sep;3(9):1041-50
pubmed: 21913827
J Biol Chem. 2018 Feb 16;293(7):2466-2475
pubmed: 29196603
Biomedicines. 2017 Jun 28;5(3):
pubmed: 28657611
Melanoma Res. 2008 Apr;18(2):73-84
pubmed: 18337643
Thyroid. 2021 Oct;31(10):1481-1493
pubmed: 34078123
Cancers (Basel). 2019 Aug 16;11(8):
pubmed: 31426437
N Engl J Med. 2014 Nov 13;371(20):1867-76
pubmed: 25265494
Oncol Rep. 2021 Apr;45(4):
pubmed: 33649790
Cancer Biol Ther. 2007 Jun;6(6):846-52
pubmed: 17495524